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Abstract The prion, the transmissible agent that causes 
spongiform encephalopathies such as serapie, bovine spongiform 
encephalopathy (BSE) and Creutzfeldt-Jakob disease, is be- 
lieved to be devoid of nucleic acid and identical with PrP so, a 
modified form of the normal host protein PrP ¢ which is encoded 
by the single cop~v gene Prnp. The 'protein only" hypothesis 
proposes that PrP ~c, when introduced into a normal host, causes 
the conversion of PrP c into prpS~; it therefore predicts that an 
animal devoid of PrP c should be resistant o prion diseases. We 
generated homozygous Prnp °1° ('PrP knockout') mice and 
showed that, after inoculation with prions, they remained free 
of scrapie for at least 2 years while wild-type controls all died 
within 6 months. There was no propagation of prions in the 
Prnp °t° animals. Surprisingly, heterozygous Prnp °t+ mice, which 
express PrP c at about half the normal level, also showed 
enhanced resistance to scrapie disease despite high levels of 
infectious agent and PrP ~c in the brain early on. After 
introduction of murine PrP transgenes Prnp °t° mice became 
highly susceptible to mouse but not to hamster prions, while the 
insertion of Syrian hamster PrP transgenes rendered them 
susceptible to hamster but to a much lesser extent to mouse 
prions. These complementation experiments paved the way to the 
application of reverse genetics. We have prepared animals 
transgenic for genes encoding PrP with amino terminal deletions 
of various lengths and have found that PrP lacking 48 amino 
proximal amino acids, which comprise four of the five octa 
repeats of PrP, is still biologically active. 
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1. Introduction 
tion. The agent was later designated 'prion' to distinguish it
from conventional pathogens such as bacteria nd viruses [1]. 
In a separate development, a number of slow degenerative 
human diseases of the central nervous ystem were recognized, 
namely kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann 
Str/iussler-Scheinker disease (GSS) and fatal familial insom- 
nia (FFI). Although CJD, GSS and FFI are rare diseases, 
found only once per 106-107 individuals per year, kuru as- 
sumed epidemic proportions in the first decades of this cen- 
tury in Papua New Guinea. Inoculation studies by Gajdusek 
and his colleagues resulted in the transmission of kuru to 
chimpanzees [2,3] and by now all human prion diseases 
have been transmitted to experimental nimals, including 
the mouse. It is believed that kuru was propagated by ritual 
cannibalism [4,5] and may have originated with the consump- 
tion of the remains of a CJD sufferer. 
In recent years a new form of prion disease emerged in 
Great Britain, and to a lesser extent in other European coun- 
tries, namely bovine spongiform encephalopathy (BSE) or 
mad cow disease, which has been attributed to the consump- 
tion by cattle of feed supplements derived from scrapie-con- 
taminated sheep and later from cattle offal [6]. In my view, it 
is however equally possible that BSE originated as a sporadic 
case in cattle and was then spread by contaminated cattle 
offal. Because there has quite recently been a cumulation in 
Great Britain of CJD-like disease with novel neuropathologi- 
cal features in humans below the age of 35 [7], there is reason 
to believe that BSE may have been transmitted to man via the 
consumption of contaminated bovine offal. The use of bovine 
offal for consumption by humans and ruminants has been 
interdicted in Great Britain since 1989. 
Scrapie was described some 250 years ago as a sheep disease 
presenting with excitability, itching, ataxia and finally paraly- 
sis and death. In the past decades it has been studied as the 
prototype of what has proved to be a group of diseases affect- 
ing not only animals but also humans, the transmissible spon- 
giform encephalopathies (TSEs) or prion diseases. It was early 
on recognized that the transmissible agent had quite extraor- 
dinary properties, such as unusually long incubation periods, 
measured in months to years and uncommon resistance to 
high temperature, formaldehyde treatment and UV irradia- 
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2. Some characteristics of prion diseases 
Prion diseases are unusual because they may arise sponta- 
neously in the population at large without any apparent 
cause, so-called sporadic forms. They can be familial, tightly 
linked to certain mutations of the Prnp gene or acquired by 
transplantation, i jection and possibly ingestion of contami- 
nated products; in all case the disease can usually be experi- 
mentally transmitted to mice by intracerebral inoculation. 
Although incubation times are measured in years or dec- 
ades, once the disease becomes clinically evident, progression 
to death may take as little as a few months. In man, the first 
symptoms are usually loss of memory or motor disturbances, 
leading to dementia nd death. The pathological changes in 
the brain vary in location and intensity; characteristically, 
extensive vacuolation, neuronal cell death and gliosis, singly 
or in combination are evident. Accumulation of PrP sc is the 
major pathognomonic feature; formation of amyloid plaques 
consisting mainly of PrP sc is a typical albeit not invariable 
0014-5793/96/$12.00 © 1996 Federation of European Biochemical Societies. All rights reserved. 
PII S00 1 4-5793(96)006 1 0-2 
4 C Weissmann/FEBS Letters 389 (1996) 3-11 
finding. Neither inflammatory nor immunological responses 
are observed. 
3. Hypotheses about the nature of the scrapie agent 
The unusual properties of the scrapie agent early on gave 
rise to speculations that it might be devoid of nucleic acid [8]. 
Currently, the most widely accepted proposal is the 'protein 
only' hypothesis, first outlined in general terms by Griffith [9] 
and enunciated in its updated and detailed form by Prusiner 
[10,11]. The virino hypothesis holds that the infectious agent 
consists of a scrapie-specific nucleic acid genome and host- 
derived PrP so, which is recruited as some sort of coat [12]. 
Finally, some still believe that the scrapie agent is a conven- 
tional virus with unusual properties. However, no evidence for 
the scrapie-specific nucleic acid postulated by the virus or 
virino theories has been found [13]. 
The 'protein only' hypothesis proposes that the prion con- 
tains no nucleic acid and is identical with PrP sc, a modified 
form of PrP c [10]. PrP c is a normal host protein [14-16] 
found predominantly on the outer surface of neurons (Fig. 
1). PrP sc is defined as a form of PrP c that readily forms 
protease-resistant aggregates after treatment with detergents 
[14,17]. Prusiner proposed that PrP so, when introduced into 
a normal cell, causes the conversion of PrP c or its precursor 
into PrP s~ (Figs. 1-3). The exact nature of the conversion is 
unknown but it is currently ascribed to conformational mod- 
ification [18]; it has been determined that the [~-sheet content 
of PrP s~ is high while that of PrP ¢ is low [19,20]. No chemical 
differences have so far been found between PrP c and PrP sc 
[21]. However, because the ratio of infectious units to PrP s~ 
molecules is only about 1 : 100 000 [22], the structure of the 
PrP molecule actually associated with infectivity cannot be 
definitively inferred. For this reason and because specific in- 
fectivity can vary considerably, the PrP species responsible for 
infectivity is presently better designated as PrP* [23]; it may 
or may not be identical with PrP so, the major species that has 
been characterized chemically and physicochemically. If it is 
identical, the low specific activity could be due to a low effi- 
ciency of infection or to the infectious unit being an aggregate 
of a large number of PrP sc molecules. The conclusion that 
some form of PrP is the essential, perhaps only constituent 
of the infectious agent is based on biochemical and genetic 
evidence, as outlined below. 
4. Biosynthesis of PrP c and PrP sc 
The entire PrP coding sequence is contained within one 
exon of the singular Prnp gene [16]. As shown in Fig. 3, an 
N-terminal signal sequence of 22 amino acids is cleaved off 
the primary translation product, glycosylation occurs at two 
Asn residues and 23 C-terminal amino acids are removed 
when a glycosyl phosphatidylinositol (GPI) residue is attached 
to Ser231. Mature PrP c is anchored to the outer surface of 
the plasma membrane [24] and undergoes endocytosis [25,26] 
and recycling [27]. The highest levels of PrP c are found in 
brain, particularly in the hippocampus, but substantial 
amounts are also found in heart and skeletal muscle [28] 
and lesser levels in most other organs except for liver and 
pancreas. 
No non-allelic Prnp-related genes have been identified, no 
differences between PrP c and PrP sc have been revealed by 
protein sequencing, and the amino acid sequences of both 
agree with that deduced from cloned genomic and eDNA 
a b c 
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Fig. 1. Models for the propagation of the prion. (a) In the normal cell PrP c is synthesized, transported to the cell surface and recycled (b) The 
Sc C 'protein only' model assumes that the prion is identical with PrP ". Exogenous prions cause the conversion of the normal cellular protein PrP 
Sc into PrP sc , either at the cell surface or after internalization. (c) PrP accumulates intracellularly, in late endosomes or lysosomes and the cell 
surface is depleted of PrP c. PrP c is also released into the extracellular space. 
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Fig. 2. Models for the conformational conversion of PrP c to PrP sc. 
(a). The 'refolding' model. The conformational change is thermody- 
namically controlled: a high activation energy barrier prevents pon- 
taneous conversion at detectable rates. As a result of an interaction 
with exogenously introduced PrP so, PrP c undergoes an induced con- 
formational change to form PrP so. This reaction may involve exten- 
sive unfolding and refolding of the protein to explain the postulated 
high energy barrier and could be dependent on an enzyme or cha- 
perone. The process leads to an exponential conversion cascade. In 
the case of certain mutations in PrP c, spontaneous conversion to 
PrP sc may occur as a rare event, explaining why familial CJD or 
GSS arise spontaneously, albeit late in life. Sporadic CJD may 
come about when an extremely rare event (occurring in one among 
a million individuals per year) leads to spontaneous conversion of 
PrP c to PrP s~ and gives rise to a conversion cascade [10,35]. (b). 
The 'seeding model'. The conformational change is kinetically con- 
trolled: the conformational change between PrP c and PrP s~ or a 
prpS~-like molecule is reversible. PrP sc is only stabilized when it 
adds onto a crystal-like seed or aggregate of PrP so. Seed formation 
is kinetically controlled and extremely slow; once a seed is present, 
monomer addition can ensue at a rapid rate [58,59]. 
[16,21,29]. Pulse-chase xperiments in scrapie-infected neuro- 
b lastoma cells suggest hat PrP c is converted to PrP sc either 
at the cell surface or following endocytosis [30]. In brain, 
PrP s~ accumulates to a level up to 100 times higher than 
that of PrP c, however PrP mRNA levels are the same in 
normal  and scrapie-infected tissue. 
5. Physical linkage of PrP sc and prions 
Purification of scrapie infectivity led to preparations con- 
taining PrP s~ as major  protein component  [31]. Conversely, 
immunoaff inity purification of scrapie-infected hamster brain 
extracts using antibodies against PrP (there are currently no 
antibodies discriminating between PrP c and PrP s~) led to en- 
r ichment of infectivity [32]. These experiments show that the 
infectious agent is physically associated with PrP sc or a mol- 
ecule very similar to it, but do not preclude the association of 
the PrP-derived molecule with another component.  It has, 
however, been shown that highly purified prion preparations 
contain less than one molecule of nucleic acid larger than 
about  100 nucleotides [33]. 
6. Genetic evidence linking the PrP gene with prion disease 
Prions are transmitted from one species to another much 
less inefficiently, if at all, than within the same species and 
only after prolonged incubation times. In the case of prion 
transmission from hamsters to mice, this so-called species bar- 
rier was overcome by introducing hamster Prnp transgenes 
into recipient wild-type mice [34,35]. Importantly,  the proper- 
ties of the prions produced in these transgenic mice corre- 
sponded to the prion species used for inoculation [35], that 
is, infection with hamster  prions led to product ion of hamster 
prions but infection with mouse prions gave rise to mouse 
prions. Within the framework of the 'protein only' hypothesis 
this means that hamster PrP c but not murine PrP c (which 
differs from the former by 10 amino acids), is a suitable sub- 
strate for conversion to hamster PrP sc by hamster prions and 
vice versa. 
Most, if not all familial forms of human spongiform ence- 
phalopathies are linked to one of a number  of mutat ions in 
the PrP gene [36]; for reviews see [37,38]. Prusiner [10,39] 
proposed that the mutat ions allow spontaneous conversion 
of PrP ¢ into PrP s~ with a frequency sufficient o allow expres- 
sion of the disease within the lifetime of the individual. Spo- 
radic C JD could be attr ibuted to rare instances of sponta- 
neous conversion of PrP c into PrP sc or rare somatic 
mutat ions in the Prnp gene. In both cases the initial conver- 
sion is thought  to be followed by autocatalytic propagation. 
Hsiao et al. [36] showed that mice overexpressing a murine 
PrP transgene with a mutat ion corresponding to the human 
GSS mutat ion Pro l02~ Leu spontaneously contract a lethal 
scrapie-like disease. The brains of these animals contain low 
levels of infectious prions which can be detected in indicator 
mice expressing the same mutant  ransgene but at lower levels 
which do not lead to spontaneous disease [40]. 
Table 1 
Prion titers in brain and spleen of Prnp +/+ and Prnp °/° mice 
Time after Log LDs0 units/ml 
inoculation 
Brain Spleen 
Prnp +/+ Prnp °/° Prnp +/+ Prnp °/° 
4 days <1.5 2.0 5.7+0.9 2.3 
2 weeks <1.5 <1.5 6.2+0.8 <1.5 
8 weeks 5.4 <1.5 6.9 + 1.0 <1.5 
12 weeks 6.8 <1.5 5.9+0.6 <1.5 
20 weeks 8.6 <1.5 6.9+0.6 <1.5 
23/25 weeks 8.1 +0.8 <1.5 n.d. <1.5 
Mice with the genotype indicated were inoculated intracerebrally with 
mouse prions. Titers were determined by end point titration on homo- 
genates of pooled organs from 4 mice after heating for 20 min at 80C. 
Data from [41]. 
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7. Resistance to scrapie of mice devoid of PrP c 
The 'protein only' hypothesis predicts that in the absence of 
PrP c mice should be resistant to scrapie and fail to propagate 
the infectious agent. 
To generate mice devoid of PrP, we disrupted one Prnp 
allele of murine embryonic stem (ES) cells by homologous 
recombination with a recombinant DNA fragment in which 
two thirds of the 254-codon open reading frame were replaced 
by extraneous DNA. The ES cells were introduced into blas- 
tocysts, from which chimeric mice were generated. Appropri- 
ate breeding ave rise to offspring homozygous for the dis- 
rupted Prnp gene (Prnp°/°). PrP was undetectable in Prnp °/° 
brains and present at about half the normal evel in the brains 
of heterozygous (Prnp °/+ ) mice [41]. No abnormalities were 
noted in Prnp °l° mice at the macroscopic, microscopic or be- 
havioral evels [41]. The suggestion that there may be a syn- 
aptic deficiency in Prnp °/° mice [42,43] has not been confirmed 
[44]. The claim that aged mice (with a mixed genetic back- 
ground) develop ataxia and suffer a loss of Purkinje cells [45] 
as a consequence of PrP gene disruption is not consistent with 
previous investigations on independently generated Prnp °/° 
mouse lines [41,46]. Because the phenotype might be due to 
the undefined, mixed genetic background of the knockout 
mice [47], it is necessary to show that complementation with 
a PrP transgene restores the normal phenotype. 
When challenged with mouse prions, mice devoid of PrP 
were completely protected against scrapie disease (Fig. 4A). 
Prions were not propagated in brains of Prnp °/° mice at de- 
tectable levels, while in scrapie-inoculated Prnp +/÷ animals 
infectious agent was absent up to 2 weeks after inoculation 
(p.i.) but was present at 8 weeks and increased to about 8.6 
log LDs0 units/ml by 20 weeks p.i. (Table 1) [48,49]. As op- 
posed to brain, spleen of Prnp +/+ animals contained infectivity 
at the earliest ime point tested, namely 2 days p.i. and in- 
creased thereafter to a level of about 7 log LDs0 units/ml. In 
contrast, spleen of knockout animals howed only a low prion 
level at 4 days p.i., which thereafter became undetectable, 
suggesting that prions are initially transported from the intra- 
cerebral injection site to the spleen, where they are soon de- 
graded. It had previously not been clear whether infectivity in 
spleen of wild-type animals, particularly at early times, was 
due to transport from the site of inoculation or whether it was 
synthesized in the spleen itself. The fact that in spleen of wild- 
type animals the prion titer is high at 2 weeks, when no in- 
fectivity is found in the brain, coupled with the fact that in 
knockout animals inoculum-derived infectivity has disap- 
peared by that time, strongly suggests that in wild-type ani- 
mals prions are in fact synthesized in the spleen. It is, inciden- 
tally, quite puzzling that following intracerebral injection 
prion synthesis occurs so early in spleen and only after a 
long delay in brain. 
Interestingly, even heterozygous Prnp °/+ mice were partially 
protected, inasmuch as they showed prolonged incubation 
times of about 290 days as compared to about 180 days in 
the case of the wild-type controls. Moreover, the disease pro- 
gressed much more slowly in Prnp °/+ mice than in Prnp +/+ 
mice, the interval between first symptoms and death being 
about 13 days in the case of Prnp +/+ mice and 150 or more 
days in Prnp °/+ mice (Fig. 5) [75]. These and other findings 
(see below and [35]) show that susceptibility o scrapie is a 
function of PrP c levels in the host. It is evident hat mice can 
carry high levels of scrapie infectivity and PrP s° in their brain 
without showing clinical disease; the same might be true for 
humans and other animals. 
When a modified phenotype is observed following a tar- 
geted mutation or gene disruption, it is important to show 
that the original phenotype - in this case, susceptibility to 
scrapi~ can be recovered by restoring wild-type function. 
We therefore introduced murine Prnp transgenes into Prnp °/° 
mice and obtained several lines with varying expression levels 
of PrP c. As shown in Fig. 4B, knockout mice expressing Prnp 
transgenes became susceptible to mouse prions; in fact, the 
higher the PrP c content of the brain, the shorter the incuba- 
primary translation product 
octarepeats 181 197 231 
I I 
I==1 209aa ==1 
amino terminal carboxy terminal 
signal signal 
maturation 
mature PrP C CHO C l io  C l iO  
I I protease [] []  
I ~ 209 aa L ~- [] I-I []  
E3 D D \ 
GPI [] CHO 
~1 conversion 
PrP se  CliO CHO 
~ ~ ~ ~ i i : i i J i i ~ i i i ! L k  protease ~ [] 
GPI 
PrP 27-30  CliO CHO / /  
[] \ 
GPI 
Fig. 3. Biosynthesis of PrP c and PrP so. Maturation of the PrP precursor protein involves cleavage of the signal sequence, removal of 23 C- 
terminal amino acids, attachment of a glycosyl phosphatidylinositol (GPI) anchor at Ser231 and glycosylation (CHO) at Asnl81 and Asn197. 
Mature PrP c is anchored at the outer surface of the plasma membrane and is sensitive to proteinase K. Conversion of PrP c to PrP sc occurs 
after exposure of the host to scrapie prions. PrP sc is partially resistant to proteinase K and yields PrP27-30 after digestion; the N-terminus i  
frayed and ranges from residues 73 to 90. 'Octa repeats' are repeats of almost identical sequences of 8 amino acids. 
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Fig. 4. Scrapie resistance of mice with disrupted PrP genes. (A) 
Prnp °l° mice remain symptom-free after inoculation with mouse 
scrapie prions. Prnp H+ litter mates or wild-type CD-1 mice show 
scrapie symptoms at the times indicated. Arrows: Five mice were 
killed at various times; none had scrapie symptoms. Modified from 
[48]. (B). Prnp °/° mice were rendered transgenic for Prnp genes. 
tgal9/+ mice had 34  times c the normal PrP level; tga20/+ mice 
had 6-7 times the normal evel. From [50]. (C). Prnp °/° and Prnp °/+ 
mice with hamster PrP transgenes atdifferent imes after inoculation 
with hamster scrapie prions. Groups of 9-11 mice of each genotype 
were inoculated with the Sc237 isolate of hamster prions. Arrow: 
One animal died spontaneously without scrapie symptoms and one 
was killed because of a tumor. Modified from [48]. 
tion times [50]. Even more interestingly, introduction of multi- 
ple hamster Prnp transgenes into Prnp °/° mice rendered them 
very susceptible to hamster-derived prions (56 days incubation 
time) (Fig. 4C) but much less so to mouse-derived prions (303 
days incubation time) [48], demonstrating the requirement for 
a homotypic relationship between incoming prion and resident 
PrP protein for optimal prion propagation and development of
pathology, as foreshadowed by the results of Prusiner et al. 
[35] described above. 
8. Mechanism of pathogenesis 
The mechanism of pathogenesis, i.e. the events leading to 
vacuolization and neuronal death are not yet well understood. 
Because neurons (and astrocytes) may be depleted of PrP c, it 
has been speculated that this may be the cause of cell damage 
[42]. The fact that PrP knockout animals how no scrapie-like 
symptoms and appear quite healthy would argue against his 
hypothesis, unless one postulates that chronic deprivation of 
PrP allows for the recruitment of compensatory mechanisms 
while acute depletion, as may occur in scrapie, does not. Al- 
ternatively, exposure to PrP sc may lead to toxic effects. 
Brandner et al. [51] introduced PrP-overproducing neuroecto- 
dermal grafts into brains of knockout mice; contralateral in- 
oculation with scrapie prions led to pronounced scrapie 
pathology in the graft but not in the surrounding tissue. 
Moreover, PrP sc was released by the infected graft, trans- 
ported to distant sites, presumably by diffusion within the 
extracellular space [52] and deposited in form of granules 
without causing any apparent damage to surrounding cells. 
It would seem that damage is only caused to cells expressing 
PrP c, perhaps because this leads to infection and intracellular 
processes, including accumulation of prpS% Interestingly, PrP- 
derived peptides cause toxic damage to prpC-expressing cor- 
tical cell cultures, but not to PrP °/° cultures [53,54]. 
9. Reverse genetics 
The demonstration that disruption of the PrP gene confers 
resistance to scrapie and reintroduction of a PrP-encoding 
transgene restores susceptibility to the disease opens up the 
possibility of practising reverse genetics on PrP, that is, intro- 
ducing deletions or mutations into the Prnp gene and deter- 
mining the capacity of the modified gene to confer suscept- 
ibility to scrapie to a PrP knockout mouse. 
As mentioned above, Pr0tease treatment of prion prepara- 
tions cleaves off about 60 amino terminal residues of PrP sc 
[55] but does not abrogate infectivity [56]. We introduced into 
PrP knockout mice transgenes encoding wild-type PrP or PrP 
lacking 26 or 49 amino proximal amino acids which are pro- 
tease-susceptible in prpS% Inoculation with prions led to fatal 
disease (Fig. 6), prion propagation and accumulation of PrP sc 
both in mice expressing wild-type and truncated PrPs [50]. 
Within the framework of the 'protein only' hypothesis this 
means that the amino proximal segment of PrP c, which con- 
tains 3.5 of its 5 octa repeats, is required neither for its sus- 
ceptibility to conversion into the pathogenic, infectious form 
of PrP nor for the generation of PrP so. 
10. Conversion of PrP c to PrP Sc 
Conversion of PrP c to PrP sc in scrapie-infected cells is a 
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Fig. 5. Survival, prion titers and PrP sc in brains of (A) wild type and (B) Prnp °/+ mice at various times after inoculation with mouse prions. 
From [75]. 
late post-translational process, occurring after PrP c has 
reached its normal extracellular location or thereafter [30] 
Spontaneous conversion of PrP c is obviously and luckily 
an extremely rare event. Why is this so, and how does scrapie 
infection promote conversion? The 'refolding model' (Fig. 2a) 
proposes that conversion requires unfolding PrP c to some 
extent and refolding it under the influence of a PrP sc molecule 
[39], a process which would have to overcome a high activa- 
tion energy barrier and might require a chaperone and an 
energy source. The 'nucleation model' (Fig. 2b) proposes 
that PrP c is in equilibrium with PrP sc (or a precursor thereof) 
and that PrP s° is only stabilized when it adds onto a crystal- 
like seed or aggregate of PrP so. I f  a stable aggregate needs to 
consist of a minimum of n PrP sc molecules, then the sponta- 
neous formation of such aggregates would proceed at a rate 
proportional to the nth power of the monomer concentration, 
which would explain why spontaneous disease is so rare. Once 
a seed is present, monomer addition can ensue at a rapid rate 
[57 59]. Trapping of PrP by an essentially irreversible aggre- 
gation reaction would drive the bulk conversion process. The 
proposed process is akin to the assembly of, for example, 
(protease-sensitive) flagellin to (protease-resistant) flagellar fi- 
laments [60]. Interestingly, the same flagellin molecule can 
assemble into two types of flagella, depending on the prove- 
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nance of the seed [61], thereby providing an analogy for con- 
formationally determined prion strain specificity (see below). 
Whatever the nature of the conversion process, an impor- 
tant experimental dvance [62] has been the demonstration 
that incubation of 35S-labeled biosynthetic hamster PrP c 
with about 50 fold excess of PrP sc from scrapie-infected ham- 
ster brain resulted in the conversion of some labeled protein 
into the partly proteinase K-resistant state characteristic for 
hamster PrP so. To achieve this conversion, 35S-labeled PrP c 
and PrP sc were partly denatured with 3M guanidinium chlor- 
ide prior to incubation i  a lower, critical concentration f the 
denaturant. Because of the denaturation step, the experiment 
is compatible with both the 'refolding' and the 'nucleation' 
model. The large amount of infectious agent associated with 
the PrP sc added, the modest extent of conversion and the 
imprecision of the infectivity assay currently preclude at- 
tempts to search for an increase in infectivity. The specificity 
of the reaction was documented by showing that murine PrP c 
was converted by murine PrP s~ but not by hamster PrP so, as 
would be expected from the species barrier for in vivo trans- 
mission from hamster to mouse, however in the converse re- 
action conversion was observed, perhaps reflecting the less 
stringent barrier from mouse to hamster [63]. 
11. Prion strains 
ent conformation of PrP sc (or PrP*) and that each of these 
can convert he PrP c of its host into a likeness of itself. Bessen 
et al. [66] took advantage of the finding that two hamster- 
adapted scrapie strains, HY and DY, give rise to PrP sc mo- 
lecules which are cleaved to products of different length by 
proteinase K [67]. In the in vitro system described above, 35S- 
labeled hamster PrP c incubated with DY PrP sc gave a radio- 
active proteolytic product shorter by about 1 kDa than that 
obtained after incubation with HY PrP s~, the same difference 
exhibited by the protease-resistant moieties of natural PrP sc 
molecules of the two strains. These remarkable results, if ex- 
tended to show that conversion also results in generation of 
infectivity, will definitively confirm the 'protein only' model, 
allow structural characterization f the prion and solve the 
strain problem. 
The targeting hypothesis (K.H. Meyer, pers. commun. 1991) 
[68,69] proposes that PrP sc carries a modification, for example 
carbohydrate r sidues, which varies from strain to strain and 
which targets it to a particular subset of cells. These cells 
would impart the same modification to the newly formed 
PrP sc molecules. Different strains would thus be targeted to 
different subsets of cells and retain their specific modification. 
This hypothesis supported by the observation that different 
hamster prion strains [68] or mouse prion strains [70] give rise 
to different patterns of PrP sc deposition in the brain. 
Dickinson and his colleagues [64,65] showed that many dis- 
tinct strains of scrapie prions can be derived from sheep iso- 
lates. These strains differ by their incubation times in various 
inbred mouse lines and by the lesion patterns they occasion in 
the affected brains. Interestingly, different strains can be prop- 
agated in one inbred mouse strain (homozygous with regard 
to its PrP gene) [65]. Within the framework of the 'protein 
only' hypothesis this is at first blush puzzling, because it 
means that one and the same polypeptide chain is able to 
mediate different strain phenotypes. At least two explanations 
can be considered in this connection. The eonformational hy- 
pothesis postulates that each strain is associated with a differ- 
12. Implications and outlook 
While each individual piece of evidence described above 
could be explained in several ways, the conjunction of data 
strongly supports the proposal that the prion is composed 
partly or entirely of a PrP-derived molecule (PrP* or prpSc), 
and that protein-encoding nucleic acid is not an essential com- 
ponent. Probably the closest one could come to irrefutable 
proof for the 'protein only' hypothesis would be the demon- 
stration that biosynthetic, pure PrP c can be converted not 
only into a protease-resistant form, but to infectious crapie 
agent under defined conditions in vitro. 
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Because mice with disrupted Prnp genes are viable and re- 
sistant, it should be possible to breed sheep or cattle that are 
resistant o this disease; knockout methodology is in principle 
available for sheep [71] but not yet for cattle. While it is 
hardly practical to consider complete replacement of conven- 
tional animals by PrP knockout counterparts, herds of BSE- 
resistant cattle would be useful as a source for products re- 
quired for pharmaceutical purposes. Moreover, the fact that 
Prnp °/+ heterozygous mice show prolonged scrapie incubation 
times argues that an (as yet conjectural) drug leading to mod- 
erate reduction of PrP c synthesis or one retarding the conver- 
sion of PrP c to PrP sc [72] might substantially mitigate disease 
progression in incipient cases of human spongiform encepha- 
lopathies. 
Finally one may raise the question whether prion-like 
agents cause other diseases or appear in non-vertebrate organ- 
isms. Although several human diseases accompanied by amy- 
loid formation are known, none of them have been reprodu- 
cibly transmitted. Interestingly, two yeast phenotypes are 
ascribed to 'heritable protein conversion', namely the 
[URE3] and the [psi +] systems [73,74], opening new perspec- 
tives for the elucidation of this phenomenon. 
Acknowledgements: This work was supported by the Erziehungsdirek- 
tion of the Kanton of Ziirich and grants of the Schweizerische Na- 
tionalfonds and the Human Frontier Science Program to C.W. l 
thank H. Biieler, M. Fischer, M. Aguet, A. Sailer, A. Raeber. A. 
Aguzzi, H.-P. Lipp, T. Riilicke, S. Brandner and D. Shmerling for 
their important contributions to the work carried out in Zfirich. 
References 
[1] Prusiner, S.B. (1982) Science 216, 136-144. 
[2] Gajdusek, D.C., Gibbs, C.J. and Alpers, M. (1966) Nature 209, 
794-796. 
[3] Gibbs, C.J., Gajdusek, D.C., Asher, D.M., Alpers, M.P., Beck, 
E., Daniel, P.M. and Matthews, W.B. (1968) Science 161, 388 
389. 
[4] Glasse, R. and Lindenbaum, S. (1992) in: Prion Diseases of Hu- 
mans and Animals, pp. 77 91 (Prusiner, S., Collinge, J., Powell, 
J. and Anderton, B., Eds.) Ellis Horwood, New York. 
[5] Alpers, M.P. (1968) in: The Central Nervous System, Some 
Experimental Models of Neurological Diseases, pp. 234-251 
(Bailey, O.T. and Smith, D.E., Eds.) Williams and Wilkins, 
Baltimore, MD. 
[6] Wilesmith, J.W., Ryan, J.B., Hueston, W.D. and Hoinville, L.J. 
(1992) Vet. Rec. 130, 90-94. 
[7] Will, R.G. et al. (1996) Lancet 347. 
[8] Alper, T., Cramp, W.A., Haig, D.A. and Clarke, M.C. (1967) 
Nature 214, 764-766. 
[9] Griffith, J.S. (1967) Nature 215, 1043 1044. 
[10] Prusiner, S.B. (1989) Annu. Rev. Microbiol. 43, 345-374. 
[11] Prusiner, S.B. (1993) Philos. Trans. R. Soc. Lond. Biol. 339, 239 
254. 
[12] Dickinson, A.G. and Outram, G.W. (1988) Ciba Found. Syrup. 
135, 63-83. 
[13] Kellings, K., Meyer, N., Mirenda, C., Prusiner, S.B. and Riesner, 
D. (1993) Arch. Virol. Suppl. 7, 215 225. 
[14] Oesch, B. et al. (1985) Cell 40, 735-746. 
[15] Chesebro, B. et al. (1985) Nature 315, 331-333. 
[16] Basler, K. et al. (1986) Cell 46, 417~,28. 
[17] McKinley, M.P., Meyer, R.K., Kenaga, L., Rahbar, F., Cotter, 
R., Serban, A. and Prusiner, S.B. (1991) J. Virol. 65, 1340-- 
1351. 
[18] Cohen, F.E., Pan, K.M., Huang, Z., Baldwin, M., Fletterick, 
R.J. and Prusiner, S.B. (1994) Science 264, 530-1. 
[19] Pan, K.M. et al. (1993) Proc. Natl. Acad. Sci. USA 90, 10962 
10966. 
[20] Caughey, B.W., Dong, A., Bhat, K.S., Ernst, D., Hayes, S.F. and 
Caughey, W.S. (1991) Biochemistry 30, 7672-7680. 
[21] Stahl, N., Baldwin, M.A., Teplow, D.B., Hood, L., Gibson, 
B.W., Burlingame, A.L. and Prusiner, S.B. (1993) Biochemistry 
32, 1991-2002. 
[22] Bolton, D.C., Rudelli, R.D., Currie, J.R. and Bendheim, P.E. 
(1991) J. Gen. Virol. 72, 2905 2913. 
[23] Weissmann, C. (1991) Nature 349, 569 571. 
[24] Stahl, N., Borchelt, D.R., Hsiao, K. and Prusiner, S.B. (1987) 
Cell 51, 229-240. 
[25] Caughey, B., Neary, K., Buller, R., Ernst, D., Perry, L.L., 
Chesebro, B. and Race, R.E. (1990) J. Virol. 64, 1093-1101. 
[26] Borchelt, D.R., Scott, M., Taraboulos, A., Stahl, N. and 
Prusiner, S.B. (1990) J. Cell. Biol. 110, 743-752. 
[27] Shyng, S.L., Huber, M.T. and Harris, D.A. (1993) J. Biol. Chem. 
268, 15922-15928. 
[28] Bendheim, P.E. et al. (1992) Neurology 42, 149-156. 
[29] Hope, J., Morton, L.J., Farquhar, C.F., Multhaup, G., 
Beyreuther, K. and Kimberlin, R.H. (1986) EMBO J. 5, 2591- 
2597. 
[30] Caughey, B. and Raymond, G.J. (1991) J. Biol. Chem. 266, 
18217 18223. 
[31] Prusiner, S.B., Bolton, D.C., Groth, D.F., Bowman, K.A., 
Cochran, S.P. and McKinley, M.P. (1982) Biochemistry 21, 
6942 6950. 
[32] Gabizon, R., McKinley, M.P., Groth, D. and Prusiner, S.B. 
(1988) Proc. Natl. Acad. Sci. USA 85, 6617-6621. 
[33] Kellings, K., Meyer, N., Mirenda, C., Prusiner, S.B. and Riesner, 
D. (1992) J. Gen. Virol. 73, 1025 1029. 
[34] Scott, M. et al. (1989) Cell 59, 847 857. 
[35] Prusiner, S.B. et al. (1990) Cell 63, 673-686. 
[36] Hsiao, K.K., Scott, M., Foster, D., Groth, D.F., DeArmond, S.J. 
and Prusiner, S.B. (1990) Science 250, 1587-1590. 
[37] Baker, H.F. and Ridley, R.M. (1992) Neurodegeneration 1, 3- 
16. 
[38] Goldfarb, L.G., Brown, P., Cervenakova, L. and Gajdusek, D.C. 
(1994) Philos. Trans. R. Soc. Lond. B. Biol. Sci. 343, 379 84. 
[39] Prusiner, S.B. (1991) Science 252, 1515-1522. 
[40] Hsiao, K.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91, 9126- 
30. 
[41] Biieler, H. et al. (1992) Nature 356, 577 582. 
[42] Collinge, J., Whittington, M.A., Sidle, K.C.L., Smith, C.J., 
Palmer, M.S., Clarke, A.R. and Jefferys, J.G.R. (1994) Nature 
370, 295-297. 
[43] Whittington, M.A., Sidle, K.C., Gowland, I., Meads, J., Hill, 
A.F., Palmer, M.S., Jefferys, J.G. and Collinge, J. (1995) Nature 
Genet. 9, 197-201. 
[44] Lledo, P.-M., Tremblay, P., DeArmond, S.J., Prusiner, S.B. and 
Nicoll, R.A. (1996) Proc. Natl. Acad. Sci. USA 93, 2403-2407. 
[45] Sakaguchi, S. et al. (1996) Nature 380, 528 531. 
[46] Manson, J.C., Clarke, A.R., Hooper, M.L., Aitchison, L., 
McConnell, I. and Hope, J. (1994) Mol. Neurobiol. 8, 121-7. 
[47] Gerlai, R. (1996) Trends Neurosci. 19, 177 181. 
[48] Biieler, H., Aguzzi, A., Sailer, A., Greiner, R.A., Autenried, P., 
Aguet, M. and Weissmann, C. (1993) Cell 73, 1339-1347. 
[49] Sailer, A., Biieler, H., Fischer, M., Aguzzi, A. and Weissmann, 
C. (1994) Cell 77, 967 8. 
[50] Fischer, M. et al. (1996) EMBO J. 15, 1255-1264. 
[51] Brandner, S. et al. (1996) Nature 339 343. 
[52] Jeffrey, M., Goodsir, C.M., Bruce, M.E., McBride, P.A., Fowler, 
N. and Scott, J.R. (1994) Neurosci. Lett. 174, 3942. 
[53] Brown, D.R., Herms, J. and Kretzschmar, H.A. (1994) Neuro- 
report 5, 2057-60. 
[54] Brown, D.R., Schmidt, B. and Kretzschmar, H.A. (1996) Nature 
380, 345 347. 
[55] Hope, J., Multhaup, G., Reekie, L.J., Kimberlin, R.H. and 
Beyreuther, K. (1988) Eur. J. Biochem. 172, 271 277. 
[56] McKinley, M.P., Bolton, D.C. and Prusiner, S.B. (1983) Cell 35, 
57-62. 
[57] Gajdusek, D.C. (1988) J. Neuroimmunol. 20, 95-110. 
[58] Brown, P., Goldfarb, L.G. and Gajdusek, D.C. (1991) Lancet 
337, 1019 1022. 
[59] Jarrett, J.T. and Lansbury, P.J. (1993) Cell 73, 1055 1058. 
[60] Aizawa, S.-I., Vonderviszt, F., Ishima, R. and Akasaka, K. 
(1990) J. Mol. Biol. 211, 673 677. 
C. Weissmann/FEBS Letters 389 (1996) 3-11 11 
[61] Asakura, S., Eguchi, G. and Iino, T. (1966) J. Mol. Biol. 16, 302 
316. 
[62] Kocisko, D.A., Come, J.H., Priola, S.A., Chesebro, B., Ray- 
mond, G.J., Lansbury, P.T. and Caughey, B. (1994) Nature 
370, 471-474. 
[63] Kocisco, D.A., Priola, S.A., Raymond, G.J., Chesebro, B., Lans- 
bury Jr., P.T. and Caughey, B. (1995) Proc. Natl. Acad. Sci. USA 
92, 3923 3927. 
[64] Dickinson, A.G. and Meikle, V.M. (1969) Genet. Res. 13, 213 
225. 
[65] Bruce, M.E., Fraser, H., McBride, P.A., Scott, J.R. and Dick- 
inson, A.G. (1992) in: Prion Diseases of Humans and Animals, 
pp. 497 508 (Prusiner, S.B., Collinge, J., Powell, J. and Ander- 
ton, B., Eds.) Ellis Horwood, New York, London. 
[66] Bessen, R.A., Kocisko, D.A., Raymond, G.J., Nandan, S., Lans- 
bury, P.T. and Caughey, B. (1995) Nature 375, 698 700. 
[67] Bessen, R.A. and Marsh, R.F. (1992) J. Virol. 66, 2096 2101. 
[68] Hecker, R. et al. (1992) Genes. Dev. 6, 1213-1228. 
[69] Weissmann, C., Biieler, H., Fischer, M. and Aguet, M. (1993) 
Intervirology 35, 164-175. 
[70] Manson, J., Mcbride, P. and Hope, J. (1992) Neurodegeneration 
1, 45-52. 
[71] Campbell, K.H., McWhir, J., Ritchie, W.A. and Wilmut, I. 
(1996) Nature 380, 64-66. 
[72] Demaimay, R., Adjou, K., Lasmezas, C., Lazarini, F., Cherifi, 
K., Seman, M., Deslys, J.P. and Dormont, D. (1994) J. Gen. 
Virol. 75. 
[73] Masison, D.C. and Wickner, R.B. (1995) Science 270, 93 95. 
[74] Chernoff, Y.O., Lindquist, S.L., Ono, B., Inge-Vechtomov, S.G. 
and Liebman, S.W. (1995) Science 268, 88~884. 
[75] Bfieler, H., Raeber, A., Sailer, A., Fischer, M., Aguzzi, A. and 
Weissmann, C. (1994) Mol. Med. I, 19 30. 
